Loading...
•
Dec 31, 2019
Immunovant Q3 2020 Earnings Report
Reported financial results for the third quarter ending December 31, 2019.
Key Takeaways
Immunovant reported a net loss of $11.3 million and ended the quarter with $123.5 million in cash. The company also received IND clearance to initiate a Phase 2a trial in warm autoimmune hemolytic anemia (WAIHA).
Ended the quarter with $123.5 million in cash.
Received IND clearance to initiate Phase 2a trial in warm autoimmune hemolytic anemia (WAIHA).
Research and development expenses were $5.0 million.
General and administrative expenses were $6.1 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...